Full-Time

Process Development Quality Engineer I

Posted on 10/31/2025

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

No salary listed

Minna, Inverin, Co. Galway, Ireland

In Person

Category
QA & Testing (3)
, ,
Requirements
  • Adhere to Integer's Values and all safety, environmental, security and quality requirements including QMS, Safety, Environmental and Security Management Systems, FDA regulations, company policies and operating procedures, and other regulatory requirements.
  • Minimum Education: bachelor’s degree in engineering or related technical/Science field; 3-year degree; candidates who do not meet the education requirement may be considered with 5+ years of relevant experience; combination of relevant experience and technical degree could be allowed.
  • Minimum Experience: 0-3 years of experience.
  • Specialized Knowledge: awareness of relevant Domestic and International Regulations and Industry Standards (e.g. ISO, QSR, UL, MDD, TGA etc.), good knowledge in Microsoft Office, ability to work independently as well as collaboratively with other associates and cross functional teams.
  • Specialized Skills: solid technical aptitude with ability to contribute to a team or produce results of a technical nature as an individual; competencies in written and oral communications; for outside of US countries, English communications; maintain a calm demeanor in a high energy production environment; positive, can-do attitude.
  • Other requirements related to regulatory compliance and quality systems (e.g., ability to support regulatory inspections, audits, investigations, inquiries, and importance of quality and QMS).
Responsibilities
  • Adhere to Integer’s Values and all safety, environmental, security and quality requirements including, but not limited to: Quality Management Systems (QMS), Safety, Environmental and Security Management Systems, FDA regulations, company policies and operating procedures, and other regulatory requirements.
  • NPI Support: you will support regulatory and agency inspections, audits, investigations, and inquiries regarding the control and assessment of product design and manufacturing quality.
  • Under supervision, you will assist in the development of new test methods and in the improvement of existing methods including design and manufacture of new tooling, fixtures, and templates.
  • Assist in the testing and validation of new test methods including gage R&R studies and statistical analysis of data through software packages such as Minitab.
  • Update test method procedures and design assurance standard operating procedures as required.
  • Provide technical input into root cause analysis. Generate investigation reports within KPI metrics and timelines and route for approval. Participate and provide technical input on cross functional reviews of New products and processes.
  • Review procedures, protocols, reports, and other documents related to NPI, test method development, product development and product testing and product validation which may be associated with new product development and introduction.
  • Be a member of a Cross Functional Project Team, providing support and expertise for the development of new products through NPI. Participate and provide technical input in line with the product development process (PDP) and associated procedures.
  • Ensure compliance at all stages of product development process (PDP) at the receiving site for NPI projects.
  • Support planning execution of risk management activities per ISO14971.
  • Under supervision, carry out periodic reviews of internal and external standards and identify potential gaps which require action.
  • Monitor manufacturing of assigned products, assuring compliance with DMR while providing deviation/waiver guidance and assuring complete and correct Device History Records are maintained.
  • Review the adequacy and correctness of changes to Bill of Materials (BOM’s), Assembly Procedures, Drawings, Component Specification, FMEAs, Control Plans, etc.
  • Participate in continuous improvement projects.
  • Assist with product transfers.
  • Collaborate with others in the exchange of information, ask questions and regularly check for understanding in support of your development as an engineer.
  • Create Test Methods: you will support generation and completion of protocols and reports for test method validations.
  • Interface with Manufacturing Engineers to review processes for new and existing products and coordinate process validations and capability studies. Recommends process monitoring devices where applicable.
  • Develop various inspection techniques and procedures to ensure product integrity to design specifications. Responsible for the writing, approval and implementation of Incoming, In-Process and Final Inspection procedures.
  • Support Non-Conforming Material Process: you will ensure that the disposition of non-conforming materials meet all necessary procedures and assure adequacy of corrective actions to prevent re-occurrence.
  • Lead and manage complaint investigations.
  • Participate in plant CAPA activities, including analysis of data and trends in complaints, supplier quality, nonconforming material, training effectiveness, and root causes analysis.
  • Apply standard data analysis practices and observe products and processes to establish root cause for product and process failures or to support the justification for improvements to products and processes.
  • Support Site Quality Activities: you will support internal quality audit activities, as applicable.
  • Embed Quality – “I own Quality.” You are a standard bearer for Quality in everything we do at Integer, by assuring adherence to our Quality Management System (QMS), supporting corrective and preventive actions investigation and implementation, and contributing to the successful attainment of our quality KPI’s and journey to differentiated quality.
  • You may perform other duties as needed and as directed by your line of supervision.
  • Support Integer’s Manufacturing Excellence and Market Focused Innovation Strategies: Strategy Alignment through Site Hoshin Plans, Quality Plans, Validation master plans, associated quality improvement imperatives, and regular updates to QA/RA weekly and monthly metrics, supporting the journey to differentiated quality.
  • Leadership of Sustained Change: ensuring customer change notifications are initiated and completed, as necessary, and supporting continuous improvement activities as required.
  • Standardization: through workplace organization & visual controls (5S), Manufacturing Standard Work, and robust training & certification programs where applicable.
  • Associate Engagement: promoted through the adoption of standardized problem solving methodologies, behavior-based safety programs, and improvement idea and suggestion systems.
  • Systems & Process Optimization: through adoption of principles of built-in-quality.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Simplify Jobs

Simplify's Take

What believers are saying

  • Board initiated strategic review on April 30, 2026, exploring sale options.
  • Irenic Capital acquired $99M stake in Q4 2025 as top holding.
  • $200M share repurchase authorization signals management confidence in valuation.

What critics are saying

  • Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
  • Three new products cause 3-4% headwind, slashing H2 2026 margins.
  • Irenic activism forces sale at depressed valuation below $93 target in 12 months.

What makes Integer Holdings Corporation unique

  • Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
  • Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
  • Robust pipeline targets above-market growth by 200 basis points in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.

Yahoo Finance
Feb 19th, 2026
Integer faces 2026 headwinds from delayed product launches despite $200M buyback and robust pipeline

Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.

INACTIVE